TIDMAGL
RNS Number : 2366Q
Angle PLC
28 November 2016
For immediate release 28 November 2016
ANGLE plc
("ANGLE" or the "Company")
ISSUE OF SHARE OPTIONS
ANGLE plc (AIM: AGL; OTCQX: ANPCY), the specialist medtech
company, announces that under the shareholder approved Remuneration
Policy the Remuneration Committee has approved the issue of
1,500,000 share options to the Company's executive directors. The
Remuneration Committee has also approved the issue of 1,805,000
share options to certain staff.
Following the issue of these share options, the Company will
have outstanding options over a total of 10,365,806 ordinary shares
of GBP0.10, representing approximately 11.6% of its issued and to
be issued share capital. This leaves approximately 3.9 million
options unallocated within the approved limit of up to 16% of the
issued and to be issued share capital from time to time.
The exercise price for the new share options is 64.50 pence per
share, representing the Company's closing mid-market share price on
25 November 2016, being the latest practicable date prior to this
announcement. The options are subject to service and/or performance
conditions.
The new share options granted to the executive directors have a
term of ten years and are subject to the performance condition that
the share price has risen by at least 100% from the share price
when the option is issued.
Following the issue of the new share options, the total number
of share options held by the executive directors of the Company
will be:
Options issued Total options
held following
issue
------------------------ --------------- ----------------
Andrew Newland, Chief
Executive 1,000,000 4,023,826
------------------------ --------------- ----------------
Ian Griffiths, Finance
Director 500,000 2,046,980
------------------------ --------------- ----------------
The non-executive directors do not hold share options.
The below notification made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
1 Details of the person discharging managerial
responsibilities / person closely associated
--- -----------------------------------------------------------
a) Name Andrew Newland
--- -------------------------- -------------------------------
2 Reason for the notification
--- -----------------------------------------------------------
a) Position/status Chief Executive Officer
--- -------------------------- -------------------------------
b) Initial notification Initial notification
/Amendment
--- -------------------------- -------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- -----------------------------------------------------------
a) Name ANGLE plc
--- -------------------------- -------------------------------
b) LEI N/A
--- -------------------------- -------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- -----------------------------------------------------------
a) Description of the Ordinary shares of 10p each
financial instrument,
type of instrument
ISIN: GB0034330679
Identification code
--- -------------------------- -------------------------------
b) Nature of the transaction Grant of options over ordinary
shares at an exercise price
of 64.5p per share
--- -------------------------- -------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---------- ----------
Nil 1,000,000
---------- ----------
--- -------------------------- -------------------------------
d) Aggregated information
- Aggregated volume N/A
- Price
--- -------------------------- -------------------------------
e) Date of the transaction 28 November 2016
--- -------------------------- -------------------------------
f) Place of the transaction Outside a trading venue
--- -------------------------- -------------------------------
1 Details of the person discharging managerial
responsibilities / person closely associated
--- -----------------------------------------------------------
a) Name Ian Griffiths
--- -------------------------- -------------------------------
2 Reason for the notification
--- -----------------------------------------------------------
a) Position/status Finance Director
--- -------------------------- -------------------------------
b) Initial notification Initial notification
/Amendment
--- -------------------------- -------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- -----------------------------------------------------------
a) Name ANGLE plc
--- -------------------------- -------------------------------
b) LEI N/A
--- -------------------------- -------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- -----------------------------------------------------------
a) Description of the Ordinary shares of 10p each
financial instrument,
type of instrument
ISIN: GB0034330679
Identification code
--- -------------------------- -------------------------------
b) Nature of the transaction Grant of options over ordinary
shares at an exercise price
of 64.5p per share
--- -------------------------- -------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---------- ----------
Nil 500,000
---------- ----------
--- -------------------------- -------------------------------
d) Aggregated information
- Aggregated volume N/A
- Price
--- -------------------------- -------------------------------
e) Date of the transaction 28 November 2016
--- -------------------------- -------------------------------
f) Place of the transaction Outside a trading venue
--- -------------------------- -------------------------------
For further information:
ANGLE plc 01483 685830
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Cenkos Securities
Stephen Keys (Nominated adviser)
Russell Kerr, Olly Baxendale
(Sales) 020 7397 8900
FTI Consulting
Simon Conway, Mo Noonan,
Stephanie Cuthbert 020 3727 1000
Kimberley Ha (US) 001 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a specialist medtech company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, China and
Australia and three extensive families of patents are being
progressed worldwide. The system is based on a microfluidic device
that captures live cells based on a combination of their size and
compressibility. Parsortix has a CE Mark for Europe and FDA
authorisation is in process for the United States.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi-billion dollar clinical market. The Parsortix
system is designed to be compatible with existing major medtech
analytical platforms and to act as a companion diagnostic for major
pharma in helping to identify patients that will benefit from a
particular drug and then monitoring the drug's effectiveness.
As well as cancer, the Parsortix technology has the potential
for deployment with several other important cell types in the
future.
ANGLE stock trades on the AIM market of the London Stock
Exchange under the ticker symbol AGL and in New York on the OTC-QX
under the ticker symbol ANPCY. For further information please
visit: www.angleplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHUBURRNNAAUUA
(END) Dow Jones Newswires
November 28, 2016 02:00 ET (07:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024
